Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma

Abstract

BACKGROUND

Para-aortic lymph nodes (PALN) are found in the aortocaval groove and they are staged as metastatic disease if involved by pancreatic ductal adenocarcinoma (PDAC). The data in the literature is conflicting with some studies having associated PALN involvement with poor prognosis, while others not sharing the same results. PALN resection is not included in the standard lymphadenectomy during pancreatic resections as per the International Study Group for Pancreatic Surgery and there is no consensus on the management of these cases.

AIM

To investigate the prognostic significance of PALN metastases on the oncological outcomes after resection for PDAC.

METHODS

This is a retrospective cohort study of data retrieved from a prospectively maintained database on consecutive patients undergoing pancreatectomies for PDAC where PALN was sampled between 2011 and 2020. Statistical comparison of the data between PALN+ and PALN- subgroups, survival analysis with the Kaplan-Meier method and risk analysis with univariable and multivariable time to event Cox regression analysis were performed, specifically assessing oncological outcomes such as median overall survival (OS) and disease-free survival (DFS).

RESULTS

81 cases had PALN sampling and 17 (21%) were positive. Pathological N stage was significantly different between PALN+ and PALN- patients (P = 0.005), while no difference was observed in any of the other characteristics. Preoperative imaging diagnosed PALN positivity in one case. OS and DFS were comparable between PALN+ and PALN- patients with lymph node positive disease (OS: 13.2 mo vs 18.8 mo, P = 0.161; DFS: 13 mo vs 16.4 mo, P = 0.179). No difference in OS or DFS was identified between PALN positive and negative patients when they received chemotherapy either in the neoadjuvant or in the adjuvant setting (OS: 23.4 mo vs 20.6 mo, P = 0.192; DFS: 23.9 mo vs 20.5 mo, P = 0.718). On the contrary, when patients did not receive chemotherapy, PALN disease had substantially shorter OS (5.5 mo vs 14.2 mo; P = 0.015) and DFS (4.4 mo vs 9.8 mo; P < 0.001). PALN involvement was not identified as an independent predictor for OS after multivariable analysis, while it was for DFS doubling the risk of recurrence.

CONCLUSION

PALN involvement does not affect OS when patients complete the indicated treatment pathway for PDAC, surgery and chemotherapy, and should not be considered as a contraindication to resection.

Key Words: Para-aortic lymph node; Pancreatectomy; Survival; Pancreatic adenocarcinoma; Chemotherapy; Lymph node sampling

Core Tip: Currently there is no consensus on the prognostic significance of para-aortic lymph node (PALN) involvement in pancreatic ductal adenocarcinoma (PDAC), which is staged as metastatic disease (M1). Our study has demonstrated that patients with PALN involvement have comparable oncological outcomes, overall survival (OS) and disease free survival, to ones without PALN disease, when the appropriate treatment pathway is competed (surgery and chemotherapy). Multivariable risk analysis did not identify PALN involvement as an independent predictor for OS, while it doubled the risk of disease recurrence. Our data support that PALN involvement should not be considered a contraindication to resection for PDAC.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) presents as localised disease for only a small subset of patients for whom only 20% are eligible for resection[1] with 5-year survival of 6.8%[2]. Nodal status is amongst the most important prognostic indicators. Early lymph node involvement can be as common as 90% and may lead to tumour recurrence even after complete resection[3]. Survival difference has been demonstrated between N0 and lymph node positive disease within variances of lymph node ratio[4] and nodal stations[5] However, para-aortic lymph nodes found in the aortocaval groove (PALN, station Ln16b1) are distinct from regional lymph node stations and are staged as distant metastatic (M1) disease[6]. PALN metastases are found in 14%-18% of pancreatic head/uncinate PDAC at resection[7]. The exact significance and management of PALN is yet to be fully determined. Within the literature, various studies have alluded to PALN metastases being associated with poor prognosis, whereas others have failed to replicate this effect[8,9] and a meta-analysis[10] has only concluded the need for intra-operative assessment of PALN. A consensus statement from the International Study Group for Pancreatic Surgery (ISGPS) supported standard lymphadenectomy for pancreatic resections, as evidence do not support any benefit with an extended approach[11]. There was no recommendation to include PALN in standard lymphadenectomy, however it was acknowledged that PALN may be included in the resection plane based on individual practice. Currently, whether intra-operative assessment should be undertaken or whether there is sufficient evidence that resection should be abandoned depends on surgeon or unit policy.

The aim of this study was to determine the prognostic significance of PALN metastases on the oncological outcomes after pancreatic resections for PDAC.

MATERIALS AND METHODS

The study was conducted in line with STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guidelines[12]. It was conducted at the University Hospitals of Birmingham, a tertiary specialist centre for the treatment of pancreatic cancer, after departmental approval. Staging of the tumours was based on the NCCN staging criteria[13]. The unit adopts a policy of fast-track[14] upfront surgery approach for resectable and borderline resectable PDAC with venous only involvement as supported by the United Kingdom National Institute for Care and Health Excellence[15], patients with borderline tumours with arterial involvement and locally advanced PDAC undergo neoadjuvant chemotherapy before resection is contemplated. All patients are referred for adjuvant chemotherapy after resection. In the early part of the study gemcitabine-based regimens were used both in the neoadjuvant and adjuvant setting. In the more recent years, modified FOLFIRINOX has been the preferred regimen, with gemcitabine-based regimens as back-up option depending on patients’ status and tolerance. PALN were sampled from the infra-renal, aortacaval lymph nodes and more specifically from the level of the third part of the duodenum to the angle of the left renal vein (station 16). PALN sampling was performed at the discretion of the operating surgeon. Over the last 3 years of the study 3 surgeons sampled PALN routinely, accounting for 36% of the cases in the study. Pre-operative staging included a computer tomography (CT) with IV contrast of the thorax, abdomen and pelvis and endoscopic ultrasound (EUS) with fine needle aspiration when preoperative cytological diagnosis was required. Magnetic resonance imaging (MRI) liver and positron emission tomography/CT (PET/CT) were used selectively if there were concerns for metastatic disease based on the CT scan. The management of all cases was discussed and agreed in the hepatopancreaticobiliary multidisciplinary meeting. Follow-up of patients was determined from time of diagnosis until disease recurrence or death. The study cohort included all patients that had PALN sampling during pancreatic resection for PDAC between 2011 and 2020. Clinical, radiological and pathological data were obtained from the hospital’s electronic records and the departmental prospectively maintained database. The American Joint Committee on Cancer 8^th edition was used for tumor-node-metastasis (TNM) staging statistical analysis. Overall survival (OS) was defined as the time from diagnosis to death or last follow-up and disease free survival as the time from resection to diagnosis of disease recurrence.

The cohort characteristics are presented with standard descriptive statistical analysis. One way Anova, Chi-Square and Mann-Whitney U tests were used as appropriate to compare variables and outcomes between PALN positive and negative subgroups, with statistical significance set at P < 0.05. Exact statistics were used for all tests to account for small sample size. Survival analysis was performed with the Kaplan-Meier method and log rank test was used to compare survival curves. Univariable and multivariable time to event analyses were performed using the Cox proportional hazard model to determine risk factors for median OS and disease-free survival (DFS). Variables were subjected to a univariable analysis first and those with P < 0.2 were introduced into a multivariable model. Hazard ratios and associated 95% confidence intervals (CI) were calculated. A two-tailed P value < 0.05 was considered statistically significant. All statistical analyses were performed using the software package SPSS Statistics for Windows (version 25.0; SPSS Inc., Chicago, IL, United States).

RESULTS

During the study period there were 81 patients who underwent pancreatectomies for PDAC where PALN were sampled. PALN metastasis was identified in 17 (21%) cases. The median sampled LNs were 2 (range 1-7) and median positivity ratio 0.5 (range 0.14-1). Patient, tumour and post-operative parameters for the whole cohort, as well as for the PALN positive and negative subgroups, are displayed in Table 1. Pathology N stage (pN) was significantly different between patients with PALN positive and negative disease (P = 0.005). All patients with PALN metastases also had regional lymph node disease, with 82% having pN2 disease (in contrast to 45% of PALN negative patients). There was no difference observed in any of the other characteristics. PALN sampling did not cause any significant morbidity in terms of chyle leak or post-pancreatectomy haemorrhage.

Table 1 Patient demographics, operative and pathological characteristics and outcomes.

Factors	Total (n = 81)	PALN+ (n = 17)	PALN- (n = 64)	P value
Demographics
Age (median and range in years)	69 (43-84)	68.8 (61-72.3)	69 (61-75)	0.404
Gender, male (%)	38 (47)	12 (71)	33 (52)	0.171
BMI (kg/m2)	25.1 (22.0-27.8)	26.2 (22.2-27.8)	24.9 (21.9-27.7)	0.413
Non-smoker (%)	13 (73)	14 (82)	46 (72)	0.462
Preoperative CA19-9 levels (KU/L)	286 (2-36000)	410 (14-2784)	252 (2-36000)	0.594
Charlson comorbidity index	4 (3-5)	4 (3-5)	4.5 (3-5)	0.079
Preoperative radiological stage n (%)
Resectable	41 (51)	8 (47)	33 (52)	0.601
Borderline resectable	31 (38)	8(47)	23 (36)
Locally advanced	9 (11)	1 (6)	8 (12)
Operation, n (%)
Distal pancreatectomy	1 (1)	0	1 (1)	0.681
Total pancreatectomy	14 (17)	2 (12)	12 (19)
Pancreaticoduodenectomy	66 (82)	15 (88)	51 (80)
Vein resection	33 (41)	7 (41)	26 (41)	0.310
Arterial resection	3 (4)	1 (6)	2 (3)	0.842
Pathological staging, n (%)				1.000
pT1	13 (16)	3 (18)	10 (16)	0.951
pT2	46 (57)	9 (53)	37 (58)
pT3	21 (26)	5 (29)	16 (25)
pT4	1 (1)	0	1 (1)
pN0	14 (79)	0	14 (22)	0.005
pN1	24 (30)	3 (18)	21 (33)
pN2	43 (53)	14 (82)	29 (45)
Resection margin, n (%)
Negative	39 (48)	6 (35)	33 (52)	0.282
Positive	42 (52)	11 (65)	31 (48)
Perineural invasion	66 (83)	15 (88)	51 (80)	0.722
Perivascular invasion	59 (73)	13 (77)	46 (72)	1.000
Chemotherapy, n (%)	55 (74)	12 (71)	43 (67)	0.746
Neoadjuvant therapy	13 (16)	2 (12)	11 (17)	0.726
Adjuvant chemotherapy	49 (66)	12 (71)	37 (58)	0.553
Post-operative complications, n (%)
Clavien Dindo category ≥ 3	10 (12)	2 (11.8)	8 (12.5)	0.549
Chyle leak	1 (1)	0	1 (1.56)	0.835
Perioperative haemorrhage	2 (2)	0	2 (3.13)	0.712
Comprehensive complication index	0 (0-20.9)	0 (0-20.9)	0 (0-20.9)	0.083
Hospital length of stay (median and range in days)	9 (1-76)	8 (5-30)	10 (1-76)	0.138

BMI: Body mass index; PALN: Para-aortic lymph nodes.

Radiological detection of PALN

Amongst patients with metastatic PALN on pathology, there was no modality of investigation which detected this during preoperative staging (CT 1/81, EUS 0/5 or PET 0/3).

OS

OS was better in PALN negative patients with a median of 20.6 mo compared to 13.2 mo in PALN positive patients (P = 0.037) (Figure 1A). However, OS among patients with lymph node disease (pN1 and pN2) was comparable between PALN positive and negative cases (13.2 mo vs 18.8 mo, P = 0.161) (Figure 1B).

Figure 1 Kaplan Meier curves comparing overall survival in patients with para-aortic lymph nodes(+) vs para-aortic lymph nodes(-). A: Total cohort; B: Patients with positive nodal disease; C: Patients who received chemotherapy; D: Patients who did not receive chemotherapy. PALN: Para-aortic lymph nodes.

Similarly, when patients were stratified based on receipt of chemotherapy, either in the neoadjuvant or the adjuvant setting, no difference in OS was observed between PALN positive and negative patients who had chemotherapy (23.4 mo vs 20.6 mo, P = 0.192). Interestingly OS of PALN positive patients was slightly longer by about 3 mo (Figure 1C). On the contrary, when patients did not receive chemotherapy, PALN metastatic disease had substantially shorter OS (5.5 mo vs 14.2 mo; P = 0.015) (Figure 1D).

Univariable Cox regression analysis showed that pT, pN, presence of PALN metastases, resection margin status and receipt of chemotherapy were associated with OS (Table 2). Multivariable analysis identified pT, pN, margin status and receipt of chemotherapy as independent predictors of survival (Table 2). Of note PALN positivity was not identified as an independent prognostic factor for OS.

Table 2 Risk analysis for overall survival.

	Univariable		Multivariable
	P value	HR (CI)	P value	HR (CI)
Age	0.668	0.994 (0.966-1.022)
Sex	0.359	0.756 (0.416-1.374)
Preoperative CA19-9	0.626	1.000 (1.000-1.000)
Pre-operative stage	0.949	0.986 (0.641-1.517)
Resection type	0.517	1.141 (0.765-1.702)
Venous resection	0.659	1.146 (0.625-2.104)
Arterial resection	0.327	2.045 (0.489-8.559)
pT	0.001	2.148 (1.368-3.371)	0.008
pT1			0.842	1.114 (0.385-3.226)
pT2			0.115	2.459 (0.803-7.536)
pT3			0.008	31.275 (2.491-392.605)
pN	0.002	2.195 (1.337-3.604)	0.004
pN1			0.329	2.332 (0.427-12.740)
pN2			0.016	7.564 (1.459-39.224)
PALN positivity	0.041	1.970 (1.028-3.776)
Margin status	0.007	2.331 (1.261-4.308)	0.049	1.986 (1.003-3.932)
Perineural invasion	0.212	1.691 (0.741-3.861)
Perivascular invasion	0.464	1.278 (0.663-2.461)
Chemotherapy	0.033	0.487 (0.251-0.944)	0.002	0.283 (0.129-0.622)

All parameters with P < 0.200 on univariable entered into multivariable model. HR: Hazard ratios; CI: Confidence intervals; PALN: Para-aortic lymph nodes.

Disease-free survival

Median DFS in the PALN positive group was 13 mo compared to 20.5 mo in the PALN negative one (Figure 2A). This approached but did not achieve statistical significance (P = 0.093). However, among patients with lymph node disease (pN1 and pN2), DFS was comparable between PALN positive and negative cases (13 mo vs 16.4 mo, P = 0.179) (Figure 2B).

Figure 2 Kaplan Meier curves comparing disease-free survival in patients with para-aortic lymph nodes(+) vs para-aortic lymph nodes(-). A: Total cohort b; B: Patients with positive nodal disease; C: Patients who received chemotherapy; D: Patients who did not receive chemotherapy. PALN: Para-aortic lymph nodes.

When the patients were stratified based on receipt of chemotherapy, either in the neoadjuvant or the adjuvant setting, no difference in DFS was observed between PALN positive and negative patients that had chemotherapy (23.9 mo vs 20.5 mo, P = 0.718). Interestingly DFS of PALN positive patients was slightly longer by about 3 mo (Figure 2C). When patients did not receive chemotherapy, PALN metastatic disease had substantially shorter DFS (4.4 mo vs 9.8 mo; P < 0.001) (Figure 2D).

Univariable Cox regression analysis showed that pT, resection margin status and receipt of chemotherapy were associated with DFS. Age, pN, PALN metastases, perineural and perivascular invasion approached but did not achieve significance (Table 3). On multivariable analysis PALN positivity was identified as an independent predictor of DFS, doubling the risk of recurrence. Other predictors were age, pT, margin status, PNI and chemotherapy (Table 3).

Table 3 Risk analysis for disease-free survival.

	Univariable		Multivariable
	P value	HR (CI)	P value	HR (CI)
Age	0.129	0.979 (0.952-1.006)	0.023	0.964 (0.933-0.995)
Sex	0.881	0.955 (0.526-1.736)
Preoperative CA19-9	0.773	1.000 (1.000-1.000)
Preoperative stage	0.943	1.016 (0.656-1.573)
Resection type	0.215	1.272 (0.869-1.862)
Venous resection	0.739	0.899 (0.481-1.681)
Arterial resection	0.567	0.048 (0.000-1578.950)
pT	0.002	2.102 (1.308-3.378)	0.004
pT1			0.265	1.726 (0.661-4.509)
pT2			0.015	3.689 (1.287-10.576)
pT3			0.002	49.543 (4.018-610.815)
pN	0.121	1.387 (0.917-2.097)
PALN positivity	0.101	1.748 (0.896-3.410)	0.045	2.287 (1.018-5.136)
Margin status	0.032	1.927 (1.057-3.514)	0.007	2.48 (1.275-4.822)
Perineural invasion	0.103	2.084 (0.862-5.036)	0.041	2.938 (1.045-8.255)
Perivascular invasion	0.152	1.657 (0.830-3.308)
Chemotherapy	0.047	0.509 (0.261-0.992)	0.001	0.242 (0.105-0.559)

All parameters with P < 0.200 on univariable entered into multivariable model. HR: Hazard ratios; CI: Confidence intervals; PALN: Para-aortic lymph nodes.

DISCUSSION

The prognostic significance of PALN positivity has long been an area of debate. The anatomic location of PALN in the aortocaval groove and away from the peri-pancreatic area has resulted in staging these as extra-regional lymph nodes and therefore metastatic disease on TNM if involved[16]. On the other hand, PALN (LN16b1) drain lymph nodes around groups 13 and 14[7,17,18] which are commonly involved in PDAC and therefore PALN could be considered the next lymph node station involved in cases of node positive disease. Furthermore, one theory that has been proposed to explain PALN acting similarly to nodal disease rather than metastatic is that LN16 involvement is due to local invasion through the fascia of Treitz[19] and this is why it is also associated with a high incidence of positive resection margins[9,19]. In this case, PALN excision may allow extensive mesopancreas dissection[20]. The published evidence on the significance of PALN positive disease and its impact in oncological outcomes is conflicting. A consensus statement from the ISGPS suggested that extended lymphadenectomy is not indicated in pancreatic resections[11]. The same group defined standard lymphadenectomy for pancreaticoduodenectomy to include lymph nodes in the hepatoduodenal ligament (stations 5, 6, 8a, 12b, 12c), pancreaticoduodenal groove (stations 13 and 17), right side of the superior mesenteric artery (stations 14a and 14b) and for distal pancreatectomy those along the splenic artery (station 11), along the inferior border of the pancreas (station 18) and in the splenic hilum (station 10), with station 9 to be included only in pancreatic body tumours. Resection of PALN (station 16) was not recommended based on the reported poor outcomes of patients with PALN positive disease. Nonetheless, it was acknowledged that PALN may be included in the resection plane based on individual practice. Some studies have stated no impact of PALN involvement on survival[7,19,21] with others suggested the opposite and even abandoning resection if this is identified intra-operatively upon sampling[8,22,23]. A confounding flaw in many studies is the comparison of survival between PALN+ and PALN-, where the latter group includes a subgroup of N0 patients with invariably better survival rates. A meta-analysis by Agalianos et al[9] made a pertinent comparison of PALN+ with pN1 PALN- patients, showing that survival rates at 1 and 2 years were significantly worse in PALN+ group. This was contested by Hempel et al[6] who showed that the OS of PALN+ and pN1 PALN- patients were not significantly different. In our study all PALN positive patients also had regional lymph node disease, whereas 22% of PALN negative patients were staged as pN0. No significant difference in OS and DFS was identified in regional lymph node positive (pN1 and pN2) PALN positive patients compared to PALN negative ones. Given that resection in the presence of nodal disease has been shown to prolong survival[24-28] there is no indication on this basis to abandon resection.

The appropriateness of PALN+ being termed M1 disease has also been challenged where long term survival after PALN+ resection has been achieved by various studies[6,29,30] including a multicentre study of 102 (12.4%) PALN+ which has shown survival of 2 years of PALN+ patients[20]. Our study covers a 10 year period during which the chemotherapy practice has changed from single agent gemcitabine to gemcitabine combined with capecitabine and more recently FOLFIRINOX. This along with the fact that approximately 30% of patients did not receive any systemic treatment can explain the OS of 20.6 mo in PALN negative and 13.2 mo in PALN positive patients. However, in patients who received chemotherapy, whether NAT or adjuvant chemotherapy, this disparity disappeared. Furthermore, on multivariable analysis PALN positivity was not an independent predictor for OS. Interestingly, OS was slightly longer in the PLAN positive patients after chemotherapy (23.4 mo vs 20.6 mo). This may reflect a treatment selection bias by the oncology teams as patients with more aggressive disease received more commonly chemotherapy in the adjuvant period (71% for PALN positive disease compared to 58% for PALN negative), even though this difference did not reach statistical significance. During the same time period, patients diagnosed with metastatic disease intra-operatively had a medial OS of 14.1 mo after palliative treatment (6.1 mo if they did not receive any palliative treatment), which is substantially less than the 23.4 mo OS recorded for PALN+ patients with chemotherapy.

Similarly, DFS was only worse in PALN positive patients if they did not receive any systemic treatment. However, in patients that had systemic treatment DFS was slightly longer in PALN positive patients (23.9 mo vs 20.5 mo). Similar to OS, this is most likely a reflection of oncological treatment selection bias. Furthermore, the fact that PALN positivity was identified on multivariable analysis as an independent predictor of DFS, doubling the risk for recurrence, is not an unexpected finding, as nodal disease is a well established prognostic factor for recurrence of PDAC.

The survival benefit of completion of the treatment pathway (surgery and chemotherapy) in patients with PDAC is well established and the sequence of chemotherapy is based on preoperative staging (neoadjuvant or adjuvant setting)[31,32]. With regards to PALN involvement, this is further supported by the results of this study as well as others on PALN disease[20,33,34]. Therefore, the comparable OS and DFS after completion of the whole treatment, surgery and chemotherapy, suggest that PALN should not be considered as a contraindication for resection if identified intra-operatively. The substantially worse OS in patients who did not receive any chemotherapy, stresses the importance of considering PALN positive disease in preoperative staging as an indication for NAT. Pre-operative CA19-9 Levels have been associated with PALN+[20,23,35]. Nonetheless, preoperative staging investigations have a very low sensitivity for this in the current as well as other studies to provide the required confirmation. The sensitivity of CT and MRI has been suggested to be close to zero for PALN+[36] while ¹⁸F-flurodeoxyglucose positron emission tomography (FDG-PET) was shown to have sensitivity 37%-50%[37-39]. EUS is used for staging of nodal involvement with accuracy reaching around 65%[40,41] though one small study of 21 patients with PALN+ was shown to have 95% sensitivity[42]. In our study only one case of PALN metastasis was identified on preoperative staging scans, while operative excisional sampling upstaged the diagnosis in 21% of the cases without increasing the risk of peri-operative complications.

The limitations of this study include its retrospective and single centre nature, as well as the selection bias associated with intra-operative PALN sampling. Additionally, as the study covers a 10 year period with changes in the preferred systemic treatment regimens for PDAC, systemic treatment selection time bias is inevitable. The small number of PALN positive patients precluded a subgroup analysis of types and duration of NAT or adjuvant chemotherapy. Despite these limitations, the study accurately reflects the practice around PALN over the previous decade and the results clearly add to the body of evidence advocating against considering PALN involvement in the absence of evidence of distant metastases as unresectable disease and against treating these patients with palliative intent.

CONCLUSION

This study suggests that PALN sampling is safe and should be routinely performed during resection of PDAC for accurate staging, even in the absence of involvement in the pre-operative imaging. PALN involvement does not affect OS when patients complete the indicated treatment pathway (surgery and chemotherapy) and occult involvement identified intra-operatively should not be considered as a contraindication to resection. Future studies should focus on improving pre-operative diagnosis and on the value of NAT for these cases.

ARTICLE HIGHLIGHTS

Research background

Pancreatic ductal adenocarcinoma (PDAC) presents as localised disease for only a small subset of patients for whom only 20% are eligible for resection with 5-year survival of 6.8%. Nodal status is amongst the most important prognostic indicators. Para-aortic lymph nodes found in the aortocaval groove (PALN) are staged as distant metastatic (M1) disease and are found in 14%-18% of pancreatic head/uncinate PDAC at resection. Various studies have alluded to PALN metastases being associated with poor prognosis, whereas others have failed to replicate this effect and a meta-analysis has only concluded the need for intra-operative assessment of PALN. A consensus statement from the International Study Group for Pancreatic Surgery supported standard lymphadenectomy for pancreatic resections, which does not include PALN.

Research motivation

Currently, whether intra-operative assessment of PALN should be undertaken or whether there is sufficient evidence that resection should be abandoned depends on surgeon or unit policy.

Research objectives

The aim of this study was to determine the prognostic significance of PALN metastases on the oncological outcomes after pancreatic resections for PDAC.

Research methods

This is a retrospective cohort study of data from a prospectively maintained database on consecutive patients undergoing pancreatectomies for PDAC where PALN was sampled between 2011 and 2020 in a tertiary specialist centre. The study was conducted in line with STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guidelines. Staging of the tumours was based on the NCCN staging criteria. PALN were sampled from the infra-renal, aortacaval lymph nodes and more specifically from the level of the third part of the duodenum to the angle of the left renal vein (station 16). PALN sampling was performed at the discretion of the operating surgeon. Over the last 3 years of the study 3 surgeons sampled PALN routinely, accounting for 36% of the cases in the study. Follow-up of patients was determined from time of diagnosis until disease recurrence or death. OS was defined as the time from diagnosis to death or last follow-up and disease free survival as the time from resection to diagnosis of disease recurrence.

The cohort characteristics are presented with standard descriptive statistical analysis. One way Anova, Chi-Square and Mann-Whitney U tests were used as appropriate for statistical comparisons with statistical significance set at P < 0.05. Exact statistics were used for all tests to account for small sample size. Survival analysis was performed with the Kaplan-Meier method and log rank test was used to compare survival curves. Univariable and multivariable time to event analyses were performed using the Cox proportional hazard model to determine risk factors for median OS and disease-free survival (DFS). Variables were subjected to a univariable analysis first and those with P < 0.2 were introduced into a multivariable model. Hazard ratios and associated 95% confidence intervals were calculated. A two-tailed P value < 0.05 was considered statistically significant. All statistical analyses were performed using the software package SPSS Statistics for Windows (version 25.0; SPSS Inc., Chicago, IL, United States).

Research results

81 cases had PALN sampling and 17 (21%) were positive. Pathological N stage was significantly different between PALN+ and PALN- patients (P = 0.005), while no difference was observed in any of the other characteristics. Preoperative imaging diagnosed PALN positivity in one case. OS and DFS were comparable between PALN+ and PALN- patients with lymph node positive disease (OS: 13.2 mo vs 18.8 mo, P = 0.161; DFS: 13 mo vs 16.4 mo, P = 0.179). No difference in OS or DFS was identified between PALN positive and negative patients when they received chemotherapy either in the neoadjuvant or in the adjuvant setting (OS: 23.4 mo vs 20.6 mo, P = 0.192; DFS: 23.9 mo vs 20.5 mo, P = 0.718). On the contrary, when patients did not receive chemotherapy, PALN disease had substantially shorter OS (5.5 mo vs 14.2 mo; P = 0.015) and DFS (4.4 mo vs 9.8 mo; P < 0.001). PALN involvement was not identified as an independent predictor for OS after multivariable analysis, while it was for DFS doubling the risk of recurrence.

Research conclusions

This study suggests that PALN sampling is safe and should be routinely performed during resection of PDAC for accurate staging, even in the absence of involvement in the pre-operative imaging. PALN involvement does not affect OS when patients complete the indicated treatment pathway (surgery and chemotherapy) and occult involvement identified intra-operatively should not be considered as a contraindication to resection.

Research perspectives

Future studies should focus on improving pre-operative diagnosis and on the value of NAT for these cases.